Abstract

The invention relates to 17-methylene steroids, process for their production and pharmaceutical compositions that contain these compounds.

The compounds according to the invention have a hybrid-type profile of action in the sense that they act as inhibitors of 5α -reductase and simultaneously as gestagens. They are therefore suitable for treating diseases that are the result of elevated androgen levels in certain organs and $\overset{\text{ff}}{\text{t}}$ tissues in men and women. Together with other hormonal $\overset{\text{ff}}{\text{t}}$ substances, such as an estrogen, testosterone or a strong androgen, the compounds according to the invention are suitable as contraceptive agents for women and for men suitable as contraceptive agents for women and for men.